New Tests Find Asbestos-Contaminated Talc in Eyeshadow

The Scientific Analytical Institute in Greensboro, North Carolina, recently uncovered asbestos-contaminated talc in two new eyeshadow makeup products sold online on sites like Amazon and eBay. Its findings were the latest example in a growing list of talc-based cosmetic products found to contain toxic asbestos. Scientific Analytical Institute found asbestos fibers in 40% of the shades tested in Jmkcoz 120 Colors Eyeshadow Palette. It found traces of asbestos in 20% of the shades tested in the Beauty Glazed Gorgeous Me Eye Shadow Tray Palette. The results were released by the Environmental Working Group in Washington, D.C., which had commissioned the laboratory testing as part of a larger investigation involving the safety of children’s products. Both products are marketed to women of varying ages. “We urge anyone who has purchased either of these products for themselves, family or friends to take necessary steps to ensure they are no longer being used,” said Tasha Stoiber, a senior scientist at the Environmental Working Group, in a press release. “And we call on these companies and online retailers to immediately pull both of these products from their respective websites.” The inhalation or ingestion of microscopic asbestos fibers can cause serious long-term medical issues, including malignant mesothelioma, lung cancer and ovarian cancer. Testing Follows FDA Asbestos-Contaminated Talc Study Talc is used with hundreds of products to absorb moistur...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news

Related Links:

A recent rise in litigation linking cosmetic talc with mesothelioma and lung cancer will continue throughout 2020, despite companies abandoning the product in the hope of avoiding costly verdicts. The number of legal cases is expected to increase by 10% this year, building on an 11% rise in 2019, according to KCIC, a well-regarded consulting firm based in Washington, D.C., that manages asbestos product liabilities. “A new trend we have started to see is talc allegations showing up in traditional asbestos complaints,” said KCIC Vice President Michelle Potter during a recent webinar that looked at past litigation...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Doctors, scientists and occupational health experts from across the country are openly criticizing the U.S. Environmental Protection Agency’s recent asbestos draft risk evaluation. At a virtual press conference arranged by the Asbestos Disease Awareness Organization last week, speakers labeled the asbestos evaluation inadequate and in need of serious revision. The year-long evaluation was required as part of the Frank R. Lautenberg Chemical Safety for the 21st Century Act, which was passed in 2016. It amended the original Toxic Substances Control Act, the country’s primary chemicals management law. “I am...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Johnson &Johnson announced Tuesday that it will stop selling its iconic, talc-based baby powder, the target of thousands of lawsuits claiming that its talc was contaminated with asbestos, which led to cancers such as mesothelioma and ovarian cancer. The company said the stoppage is only in the United States and Canada, citing a decline in consumer demand and “misinformation” about the safety of the product. “Demand for talc-based Johnson’s Baby Powder in North America has been declining due in large part to changes in consumer habits and fueled by misinformation around the safety of the product ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Conclusions: Since its introduction, PERCIST 1.0 has been increasingly used in many clinical trials and prospective studies, with variable reporting of metabolic response and survival data. In general, it appears PERCIST response is associated with longer PFS and survival though the heterogeneity of disease, scan timing and therapies make data pooling difficult. Prospective inclusion of the PERCIST 1.0 criteria in clinical trials using FDG, with baseline, early monitoring, and end of therapy scans could inform cancer clinical trials. Support: 5U01CA140204-04 Reference: 1. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: NET and Others II Source Type: research
The U.S. Food and Drug Administration found asbestos-contaminated talc in nine of the 52 cosmetic products tested during its year-long study released this week. The products with asbestos were recalled at various times throughout the past year when individual results were obtained and the public was notified. Monday’s announcement by the FDA was labeled a Constituent Update and Final Report. It also included those products that showed no trace of contamination. AMA Analytical Services Inc. in Lanham, Maryland, performed all testing for the FDA, using polarized light microscopy and transmission electron microscopy, cu...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
The U.S. Food and Drug Administration moved closer on Tuesday to formulating standardized testing of talc-based products for the presence of toxic asbestos fibers. Experts from eight different federal agencies explained earlier recommendations at a day-long hearing. The session also featured input from 25 members of the public, which included industry representatives, consumer advocates and testing experts. “Standards are needed,” said Dr. Paul Howard, FDA Office of Regulatory Science, during his presentation. “They just don’t exist at this time.” Dr. Linda Katz, director of the FDA Office of ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Doctors at the Swiss Group for Clinical Cancer Research in Zurich, Switzerland, have uncovered a novel, anti-tumor compound that could become a needed second-line treatment for pleural mesothelioma cancer. Their recent multicenter phase II clinical trial conducted in Switzerland and Italy revealed the safety and efficacy of lurbinectedin, a synthetically produced agent that inhibits the growth of mesothelioma cells. “We believe this could represent a new treatment option for pleural mesothelioma,” Dr. Yannis Metaxas, oncologist at Kantonsspital Graubunden outside Zurich, told The Mesothelioma Center at Asbestos...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
A new 33-patient case study published in the Journal of Occupational and Environmental Medicine provides some of the strongest proof yet that exposure to asbestos-tainted talcum powder may cause malignant mesothelioma, a rare and deadly cancer that affects tissues lining internal organs. This isn’t only an important scientific discovery—it could also give new ammunition to plaintiffs in the thousands of cases brought against brands selling talcum-powder-based products alleged to cause cancer, like Johnson &Johnson’s Baby Powder. “It’s very, very hard, in general, to prove exactly what caus...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Environmental Health HealthSummit19 Research toxins Source Type: news
A mesothelioma patient at West Cancer Center in Memphis, Tennessee, is the first in the country to use NovoTTF-100L, a noninvasive electric therapy treatment, since its approval by the U.S. Food and Drug Administration in May. The FDA’s approval of Novocure’s Tumor Treating Fields device for the treatment of mesothelioma marked the first new FDA-approved treatment option for the rare asbestos-related cancer in more than 15 years. NovoTTF-100L uses a low-voltage electrical field that is distributed with three pads attached to the front and back of a person’s chest. The electrical current is designed to di...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
AbstractBackgroundTumor Treating Fields (TTFields) are a non-invasive, antimitotic therapy delivered to the tumor via transducer arrays applied to the skin at tumor site. The only TTFields-related adverse event (AE) reported in clinical trials was localized dermatitis beneath the arrays. The safety of TTFields has also been investigated in glioblastoma, non-small-cell lung cancer (NSCLC), mesothelioma, pancreatic and ovarian cancer. This meta-analysis reported AEs in clinical studies with TTFields torso delivery.Methods192 patients from 4 pilot studies were included in the analysis: EF-15 (n  = 41, advanced N...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
More News: Asbestosis | Babies | Cancer | Cancer & Oncology | Environmental Health | Food and Drug Administration (FDA) | Laboratory Medicine | Lawsuits | Legislation | Lung Cancer | Mesothelioma | Minerals | Ovarian Cancer | Ovaries | Politics | Study | Toxicology | Warnings | Websites | Women